What comes next for RNA-targeted drug discovery? That question will drive several forward-looking discussions at the 9th Annual RNA-Targeted Drug Discovery & Development Summit, where experts will explore emerging biology that could dramatically expand the therapeutic reach of RNA-targeted small molecules.
A dedicated conference theme will examine how novel approaches such as condensate biology and epitranscriptomic regulation could unlock previously inaccessible targets and broaden the range of diseases addressable through RNA modulation.
Ann Boija, Chief Scientific Officer at Dewpoint Therapeutics, will present advances in the development of first-in-class condensate modulators and discuss how these programs are being applied across oncology and other disease areas.
Attendees will also hear from Andrea Casazza, Head of Cancer Biology at EPICS Therapeutics, who will explore how inhibition of RNA methyltransferases such as METTL3 is validating epitranscriptomic regulation as a novel therapeutic strategy in solid tumours.
The conference will conclude with a panel discussion featuring leaders from Sanofi, Pfizer, Ribonaut Therapeutics, and Remix Therapeutics examining what evidence is required to establish RNA-targeted small molecules as a generalizable drug modality rather than a niche approach.
With growing investment, expanding biological understanding, and increasing clinical validation, many scientists believe the next decade could see RNA-targeted therapies become a major pillar of modern drug discovery.
Download the brochure to discover the sessions exploring the future of RNA-targeted therapeutics and the opportunities beyond splice modulation.
Register your team to secure discounted rates and connect with the decision-makers and scientists pioneering tomorrow’s RNA medicines.